• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Weekly Roundup: December 14-18


ICYMI, some of the content featured this week includes a new podcast episode, a new FDA approval for actinic keratosis, examining quality of care for atopic dermatitis, plus more.

In case you missed it, some of this week’s featured content includes a new podcast episode about health care PPE dermatoses during COVID-19. Also, articles on melasma treatments, quality of care for atopic dermatitis, implementing PR into your marketing plan, a new U.S. Food and Drug Administration (FDA) approval for actinic keratosis, long-term safety and drug survival of oral systemics for psoriasis, plus more.

POLL: Patient wait times

Top 20 trending stories of 2020

For 2020, trending topics can be summed up in one word: COVID-19. But, even during a pandemic, dermatologists and the medical community at large continued to research novel therapies and seek new solutions for providing the best possible patient care. Here, Dermatology Times tracks the most compelling topics of an unprecedented year.

The Mainstream Patient: December 14

This week’s edition of The Mainstream Patient features stories on “slugging”, dermarolling, physical versus chemical exfoliants, acne scar treatments, plus more.

A successful ownership transition

Todd Petersen, CEO of VitalSkin Dermatology, discusses the last part of your transition journey – ensuring a smooth, successful transition for you, your team and your patients.

Is PR a part of your marketing plan?

Ashley Buehnerkemper, director of marketing at VitalSkin Dermatology, discusses what steps you can take to make public relations an active piece of your practice marketing.

Half of patients with AD satisfied with treatment

Half of patients are satisfied with their atopic dermatitis treatment and more than half of patients worry about topical steroid side effects, addiction and withdrawal, according to a recent study.

Emerging therapies beyond lasers

Next-generation therapies explore solutions other than laser treatments, and are less invasive, safer and require less downtime.

FDA approves topical for actinic keratosis

Tirbanibulin (Klisyri, Almirall) has been approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of actinic keratosis on the face or scalp.

The Cutaneous Connection: Episode 14- Health care PPE dermatoses during COVID-19

Since the start of the pandemic, there has been a rise in dermatoses in healthcare workers related to occupational use of personal protective equipment (PPE). Rachel Evers-Meltzer, MD, MPH, discusses her cross-sectional survey investigating what types of dermatoses were most commonly seen in the health care spear and suggests possible treatments.

Long-term safety and drug survival of oral systemics for psoriasis

Highlighting the relationship between long-term safety and drug survival, a recent review may help address physician reluctance in prescribing conventional systemic psoriasis treatments.

Identifying and improving quality of care in AD

A new innovative report identifies gaps and offers solutions for improving quality of care in atopic dermatitis (AD).

AD patients reflect high satisfaction, safety with dupilumab

A vast majority of patients with atopic dermatitis (AD) are satisfied with dupilumab (Dupixent, Sanofi and Regeneron) treatment, according to research presented at the European Academy of Dermatology and Venereology (EADV) Virtual Congress.

Treating melasma’s vascular component improves treatment outcomes, prevent relapse

Dermatologists should consider assessing melasma patients for increased vascularity and include antivascular treatments to improve outcomes among patients whose lesions have a vascular component.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.